# 4D pharma plc MHRA and HPRA clear Blautix Phase II study

- Link: https://www.directorstalkinterviews.com/4d-pharma-plc-mhra-hpra-clear-blautix-phase-ii-study/412752751
- Published: 2018-06-13T07:08:21+01:00
- Author: Giles Arbor

**4D pharma plc** (LON:DDDD), a pharmaceutical company leading the development of
live biotherapeutics, has today announced that the Company has received clearance
from the Medicines and Healthcare Products Regulatory Agency (MHRA) and the Health
Products Regulatory Authority (HPRA) to commence the Phase II study of Blautix, 
the Company’s live biotherapeutic for the treatment of Irritable Bowel Syndrome (
IBS), at sites in the UK and Ireland.

This follows an announcement made by the Company in May that the US Food and Drug
Administration (FDA) had cleared the Company’s Investigational New Drug application
to commence the Phase II study at sites in the US. Enrolment in the study is expected
to commence in the second half of 2018.

The double-blind, placebo-controlled multicentre Phase II study will evaluate the
efficacy and safety of Blautix in patients with IBS with constipation (IBS-C) and
IBS with diarrhoea (IBS-D). The Company has consulted with the FDA on the design
of the study. Up to 500 patients will receive either Blautix or placebo daily for
8 weeks. The primary endpoint will be the Overall Response rate, defined as the 
proportion of patients reporting an improvement in their weekly cohort-specific 
symptoms (abdominal pain and stool frequency or consistency) for at least 4 out 
of 8 weeks. A range of secondary efficacy endpoints will also be assessed, as well
as the effects of Blautix on the gut microbiome.

> **Dr. Alex Stevenson, 4D pharma plc Chief Scientific Officer, commented:** “We
> welcome this development which illustrates the international breadth of the study,
> set to take place at more than 10 sites across the US, UK and Ireland. This will
> be the largest live biotherapeutic clinical trial conducted to date and reflects
> our commitment to generate robust clinical data in large, well-controlled studies,
> which are aligned with the expectations of the regulatory authorities. We look
> forward to commencing enrolment of this study shortly.”

Share on:
